Kornimate/medical-research-clean huggingface dataset:
temozolomide in concomitant radiochemotherapy followed by sequential temozolomide chemotherapy - observational program (study p04816)

Conditions: Glioblastoma

Summary: the purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed glioblastoma patients in a routine care setting.

participant sampling method: consecutive patient sampling.

Eligibility criteria:
inclusion criteria: * newly diagnosed glioblastoma multiforme exclusion criteria: * history of hypersensitivity to temozolomide or its components, or to dacarbazine. * women who are pregnant or breast-feeding. * patients with severe myelosuppression.
icg use in angiography for nasoseptal flap harvest

Conditions: Skull Base Neoplasms

Summary: this is a feasibility study in which indocyanine green (icg) will be administered during routine expanded endonasal approach (eea) for cranial base pathologies in which a nasoseptal flap harvest will be necessary. the research entails administering icg, which is already widely used during open neurosurgical procedures, to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.

this study is being done to determine if it is feasible to use angiography during endo-nasal surgery. during the angiography indocyanine green (icg) will be injected into the patients iv tubing to help see the arteries. icg is routinely used in vascular surgeries on the brain but not for endo-nasal surgery. the purpose of this study is to see how well intraoperative angiography using icg can be done during endonasal surgery.

Eligibility criteria:
inclusion criteria: * age 18 and above * patients undergoing an eea for cranial base pathology that may require nasoseptal flap harvest exclusion criteria: * history of sulfa, iodide, or penicillin allergy * pregnant or breast feeding * preoperative lack of indication for nasoseptal flap harvest * previous anaphylactic reaction to icg
study of ai-based prediction models for exercise-induced gut microbiota alterations in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: this study is a randomized controlled clinical trial. the participants will be randomized into two groups in a 1:1 ratio: exercise intervention and sedentary control group. the participants (50 participants per group) will undergo a 16-week intervention. participants in the control group will maintain their sedentary lifestyle unchanged, and the exercise intervention group will receive combined aerobic and resistance exercise training. this study aims to compare the changes in gut microbiota before and after exercise intervention in patients. it will validate and optimize a cross-species microbiota mapping model through an independent exercise intervention clinical trial. additionally, it will comprehensively assess the effects of combined aerobic and resistance exercise on patients' body composition, the severity of fatty liver, and glucose-lipid metabolism indicators. the study will also analyze the correlation between dynamic changes in the gut microbiota and the improvement of clinical symptoms in patients with type 2 diabetes after exercise intervention, elucidating the regulatory mechanisms of microbiota remodeling in exercise-mediated metabolic benefits.


Eligibility criteria:
inclusion criteria: -1. diagnosed with type 2 diabetes; 2. taking ≤3 types of antidiabetic medications; 3. on a stable medication regimen for at least 6 weeks prior to the intervention and maintaining the same regimen during the study period; 4. aged between 35 and 65 years; 5. abdominal obesity: waist circumference \>90 cm for men and \>85 cm for women; 6. body mass index (bmi) ≤35 kg/m²; 7. waist-to-thigh ratio (wtr): ≥1.7 for men and ≥1.6 for women; 8. sedentary lifestyle (engaging in moderate-intensity exercise for ≤60 minutes per week). exclusion criteria: -1. glycated hemoglobin (hba1c) \<6.5% or ≥9%; 2. use of insulin; 3. presence of one or more of the following complications: advanced diabetic retinopathy, macroalbuminuria (urine albumin-to-creatinine ratio ≥300 mg/g), or renal dysfunction (estimated glomerular filtration rate \[egfr\] ≤60 ml/min/1.73 m²); 4. history of cardiovascular events (e.g., myocardial infarction, stent implantation, unstable angina, heart failure, or cardiac dysfunction); 5. history of cerebrovascular disease (e.g., cerebral hemorrhage or ischemic stroke); 6. muscular, skeletal, or neuromuscular injuries that hinder exercise training; 6. severe osteoporosis or failure to meet bone mineral density criteria despite treatment; 7. pregnancy; 8. inability or unwillingness to undergo mri examination (e.g., due to claustrophobia, implantable cardioverter-defibrillator \[icd\], or pacemaker); 9. diagnosed depression or any psychiatric disorder that prevents the patient from understanding the nature, scope, and possible sequence of the study; 10. patients taking antihypertensive or lipid-lowering medications are excluded if their medication regimen is unstable or affects glucose metabolism.
efficacy of attachment-based compassion therapy in population with chronic medical illness (cuida-tec)

Conditions: Chronic Medical Illness

Summary: compassion-based interventions are increasingly relevant as a potentially beneficial way to support people with chronic medical conditions and improve different outcomes related with the management of the disease. online interventions the purpose of this study is to evaluate the effectiveness of the internet version of the attachment-based compassion therapy for improving quality of life in a population with chronic medical illness.

our participants will be randomized to one of the following two conditions: 1) the internet version of the attachment-based compassion therapy, and 2) waiting list (wl) control group. the corresponding evaluations of the outcomes will be carried out at different moments of the process: baseline, and a three- and six-month follow-up. this study will use the internet version of attachment-based compassion therapy (iabct) for improving the quality of life in a population with chronic medical illness.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years; 2. ability to understand and read spanish; 3. access to a computer with the internet; and 4. fulfill criteria for diagnosis of one of the following chronic medical conditions: diabetes, inflammatory bowel disease, fibromyalgia, low-back chronic pain, migraines, and other conditions. exclusion criteria: 1. terminal disease; 2. severe psychiatric disorders comorbidities (schizophrenia, substance dependence, bipolar disorder, psychotic illness) or severe neurologic or medical condition; and 3. receiving psychological treatment or mindfulness training at the time of recruitment.
a randomized controlled comparison between one versus more than six months of dual antiplatelet therapy after biolimus a9-eluting stent implantation

Conditions: Coronary Artery Disease

Summary: des are preferred over bms for most patients, however prolonged dual antiplatelet therapy is required for patients treated with des for prevention of late or very late stent thrombosis. which increases a risk of major bleeding. biofreedom is a biolimus a9-coated stent that consists of a stainless steel stent platform with a textured abluminal surface without use of any polymer in the coating. biolimus a9 rapid release and polymer-free property may give biofreedom the advantages of both des and bms that may require less duration of dapt. biomatrix flex, biolimus-eluting stent with biodegradable polymer, also demonstrated safety and efficacy. we will compare these two difference types of biolimus a9-eluting stents with different duration of dapt. with proven adequate and safe duration, we will compare between one versus more than six months of dual antiplatelet therapy after biolimus a9-eluting stents implantation using different properties of biofreedom and biomatrix flex.


Eligibility criteria:
inclusion criteria: * patients ≥ 19 years old * patients with ischemic heart disease who are considered for coronary revascularization with pci * significant coronary de novo lesion exclusion criteria: * acute myocardial infarction * complex lesion morphologies such as aorta-ostial, unprotected left main, chronic total occlusion, graft, thrombosis, heavy calcified (definite calcified lesions on angiogram) or extremely tortuous lesion * need to use of dual antiplatelet therapy more than 1 month because of other medical conditions * cardiogenic shock or experience of cardiopulmonary resuscitation * contraindication or hypersensitivity to biolimus a9, stainless steel, heparin, antiplatelet agents or contrast media * history of documented prior cerebrovascular attack within 6 months * treated with any stent within 3 months * reference vessel diameter \ 4.0 mm * pregnant women or women with potential childbearing * inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator * inability to understand or read the informed content
rheolytic thrombectomy for acute deep vein thrombosis of whole lower limb

Conditions: Deep Vein Thrombosis

Summary: ipsilateral popliteal venous the most common access for pharmacomechanical thrombectomy (pmt) in the treatment of acute deep venous thrombosis (dvt), but the result was not satisfactory. the investigators adjust the access to improve the thrombus clearance rate and reduce the incidence of post-thrombotic syndrome (pts).

acute deep venous thrombosis (dvt) with whole lower limb involved is associated with significant post thrombotic morbidity. both of deep venous occlusion and valvar reflux increase the risk for development of post-thrombotic syndrome (pts). early removal of iliofemoral thrombosis by pharmacomechanical thrombectomy (pmt) may reduce the incidence of pts. in general, ipsilateral popliteal venous the most common access for pmt. however, from this approach, it's hard to remove the thrombosis in the distal popliteal vein. so, the investigators hypothesize that the residual thrombus and slow blood-flow in the in-flow may weakened the efficacy of pmt, and by adjusting vein access approach could improve the thrombus clearance rate and reduce the incidence of pts for whole leg dvt.

Eligibility criteria:
inclusion criteria: * age between 18-80 years old; * acute dvt with clinical symptoms occurred less than 14 days since the onset of disease; * dvt with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and/or calf vein; * informed consent signed by patients. exclusion criteria: * patients with the previous history of the same side of lower-limb dvt; * patients with plasma creatinine level greater than 180umol/l; * patients who are contraindicated to thrombolysis; * patients with inferior vena cava thrombosis; * patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent; * patients who have participated in a clinical trial in the past three months; * women during pregnancy and lactation * patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<2 years); * patients with autoimmune thrombopathy or thrombocytopenia (platelets \< 80·10⁹/l); * patients who are unable or unwilling to participate in the study.

Keywords: pharmacomechanical thrombectomy
ultrasonographic measurement of internal jugular vein as a predictor of hypotension following spinal anesthesia

Conditions: Spinal Anesthetics Causing Adverse Effects in Therapeutic Use; Hypotension Postprocedural

Summary: hypotension after spinal anesthesia is associated with significant perioperative morbidity and mortality, especially in hypovolemic patients. ultrasonographic measurement of internal jugular vein (ijv) has been recently shown as effective in predicting the intravascular volume status. the aim was to investigate the reliability of preanesthetic ultrasound measurements of ijv in predicting hypotension after spinal anesthesia.

hypotension after spinal anesthesia is associated with significant perioperative morbidity and mortality, especially in hypovolemic patients. ultrasonographic measurement of internal jugular vein (ijv) has been recently shown as effective in predicting the intravascular volume status. the aim was to investigate the reliability of preanesthetic ultrasound measurements of ijv in predicting hypotension after spinal anesthesia.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18-65 patients who read and accept the consent form of the study patients undergoing elective surgery under spinal anesthesia exclusion criteria: * under 18 years old, asa scores 3-4, presence of any significant hepatic, renal, cardiavasculary, or respiratory disease, having left ventricular ejection fraction less than 40%, and allergy to study medications.

Keywords: spinal anesthesia internal jugular vein hypotension ultrasonography
general anesthesia with and without muscle relaxation and muscle strength recovery

Conditions: Rocuronium; Muscle Weakness; General Anaesthesia

Summary: neuromuscular blocking agents are often used during general anesthesia. also, general anesthesia may be performed without use of neuromuscular blocking agents. avoiding neuromuscular relaxation enables better muscle strength recovery.

rocuronium is well used neuromuscular blocking agent during general anesthesia. although very often used, neuromuscular blocking agents may sometimes have consequence in form of residual neuromuscular block. tha aim of the study is to compare influence of rocuronium during general anesthesia on muscle strength recovery measured by hand grip dynamometer. measuremwnt of hand grip strength is perforrmed before and after general anesthesia. this research should contribute to better choice of anesthesia technique and better quality of patient recovery, as studies so far have not been detaily carried out. hypothesis of the research is that anesthesia without use of neuromuscular blocking agents may enable better recovery of muscle strength in immediate postoperative period.

Eligibility criteria:
inclusion criteria: * patients asa status i-iii for surgery under general anesthesia * signed informed consent for participating in research exclusion criteria: * neuromuscular disease * poorly controled chronic or acute cardiovascular, respiratory or autoimmune disease * known allergic reaction to any medication used in this research * pregnancy * refusal to participate in this research

Keywords: rocuronium muscle strength residual blockade
feasibility of a modular mhealth for tailored rehabilitation of breast cancer

Conditions: Breast Cancer

Summary: this study investigated the feasibility of the novel modular mobile health (mhealth) for personalized rehabilitation and explored the participants' satisfaction and app data during treatment of breast cancer.

this is prospective, feasible, parallel study in post-operative patients with breast cancer and during treatment. disability of arm, shoulder, hands (dash), physical activity data (ipaq-sf), physical measurement such as hand grip strength, body mass index (bmi), muscle mass, and differences in arm circumference, pro-ctcae, distress thermometer, needs and satisfaction in app, personal health record of app (exercise, daily step count, etc.) measure will be evaluated on 1-month, 2-month, 4-month, 6-month, 9-month, and 12-month after pod.

Eligibility criteria:
inclusion criteria: * unilateral breast cancer at tnm stage 0 \~ iii * patients who will undergo the treatment (chemotherapy, radiation therapy, and hormone therapy) after surgery * patients who had a mobile phone (android or ios) exclusion criteria: - patients who have metastases or recurrence to other organs were excluded
spark a healthy and fit lifestyle

Conditions: Obesity

Summary: the purpose of this study is to determine the best format for delivering a brief behavioral weight loss intervention to young adults 18-25 years of age.


Eligibility criteria:
inclusion criteria: * 18-25 years old * body mass index 25-45 * willing to be randomly assigned to any of the 3 arms * available during the time frame of the study * willing to complete assessment visits at 0, 2, 4 and 6 months exclusion criteria: * age or bmi outside of eligible range * medical condition that would interfere with weight loss or make unsupervised physical activity unsafe * pregnant or nursing within 6 months * recent weight loss \>10% of body weight * history of eating disorder * substance abuse or dependence
a research study looking at how semaglutide works in people with type 2 diabetes in canada, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how semaglutide works in real world patients. participants will get semaglutide prescribed by the study doctor. the study will last for about 6 to 8 months. participants will be asked to complete some questionnaires about the health and the diabetes treatment. participants will complete these during the normally scheduled visits with the study doctor.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * the decision to initiate treatment with commercially available semaglutide has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study * male or female, age greater than or equal to 18 years at the time of signing informed consent * diagnosed with type 2 diabetes at least 12 weeks prior to inclusion * available and documented hba1c value less than or equal to 12 weeks prior to initiation of semaglutide treatment exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * treatment with any investigational drug within 90 days prior to enrolment into the study * hypersensitivity to semaglutide or to any of the excipients
rtms in facilitation of working memory in pd

Conditions: Parkinson Disease

Summary: ten sessions of repetitive transcranial magnetic stimulation yield ability to upregulate the function of primary motor cortex and prefrontal cortex that play key roles in motor and frontal memory processing.

excitatory (\>3hz) rtms could facilitate the brain cortex and neuroplasticity that benefits motor control and working memory when the coil is applied over primary motor cortex or dorsolateral prefrontal cortex.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease * with symptoms of cognitive impairments, such as memory, attention, or language decline. exclusion criteria: * history of seizure attack * alzheimer's disease * with cardiac pacemaker implantation

Keywords: working memory parkinson's disease cognition rtms
feasibility study: higher density ulthera® system treatment with vectoring for treatment of the face and neck

Conditions: Skin Laxity

Summary: all enrolled subject will receive one ultherapy™ treatment. study images will be obtained pre-treatment, immediate post-treatment, and at each study follow-up visit. enrolled subjects will return for follow-up visits at 90 days, 180 days and 365 days post-treatment.

this is a prospective, single-center clinical trial to evaluate the efficacy of the ulthera® system to provide a customized, high-density, vectored ultherapy™ treatment to lift and tighten the skin of the face and neck. skin laxity changes from baseline will be assessed at study follow-up visits. global aesthetic improvement scale scores and patient satisfaction questionnaires will also be obtained.

Eligibility criteria:
inclusion criteria: * male or female, aged 25 to 60 years. * subject in good health. * skin laxity in the area(s) to be treated. * understands and accepts the obligation not to undergo any other procedures in the area(s) to be treated through the follow-up period. * willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. exclusion criteria: * presence of an active systemic or local skin disease that may affect wound healing. * severe solar elastosis. * excessive subcutaneous fat in the area(s) to be treated. * excessive skin laxity on the area(s) to be treated. * significant scarring in area(s) to be treated. * open wounds or lesions in the area(s) to be treated. * severe or cystic acne on the area(s) to be treated. * presence of a metal stent or implant in the area(s) to be treated. * inability to understand the protocol or to give informed consent. * bmi equal to and greater than 30.

Keywords: ulthera® system ultherapy™ treatment ulthera, inc. ultrasound treatment for skin tightening
clinical monitoring strategy versus electrophysiology-guided algorithmic approach with a new lbbb after tavi

Conditions: Left Bundle-Branch Block; Aortic Valve Stenosis

Summary: the primary hypothesis of the proposed study is that an electrophysiology-based algorithmic approach is superior to standard clinical follow-up with 30-day monitoring in reducing the combined endpoint of syncope, hospitalization, and death in patients in patients with new of left bundle branch block following transcatheter aortic valve implantation (tavi).

the study population consists of pacemaker-free patients that are 18 years or older undergoing a tavi with new onset left bundle branch block. patient consent is required. patients meeting the inclusion criteria will be randomized in a 1:1 ratio to one of the following two groups: group 1: electrophysiology-based algorithmic approach group 2: standard clinical follow-up with transcutaneous cardiac monitoring.

Eligibility criteria:
inclusion criteria: * age ≥18 years * informed consent to participate * persistent new-onset lbbb after tavi implantation (i.e. present at day 2) exclusion criteria: * prior pacemaker or implantable cardioverter-defibrillator * pre-existing right bundle branch block (rbbb) or lbbb (i.e., prior to tavi) * class i or iia indication for ppm implantation according to management guidelines